Obermatt
See Similar Stocks →

Hanall Biopharma

KSC:009420 · KR7009420001
PharmaceuticalsSmall

360

30
Profit price100
Owner Earnings Yield1
Dividend Yield1
Price/Sales1
EV / Gross Profit10
Price/Book1
Return on Capital35
Cash Return on Capital35
Return on Equity39
EBIT Margin17
Gross Profitability66
Accruals26
Owner Earnings Margin27
Sales growth55
Profit Growth8
Long-Term EPS Growth12
Owner Earnings Growth6
Reinvestment1
Price momentum100
Debt load69
Refinancing4
Debt Payback1
Liquidity18
Analyst ratings87
Opinion Changes95
Price Target Upside68
Market mood1
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Hanall Biopharma doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Websitehanall.co.kr
ISINKR7009420001
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
ImmunologyOphthalmologyPulmonologyRespiratoryNeurologyOncologyDermatologyEndocrinologyGastroenterologyDiabetesCardiovascularRheumatology

Description

Analysis

Middle-of-the-road

Hanall Biopharma Co., Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 2/20 on our value-creation score: not creating value. Analysts lean positive.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
15
2023202420252026

All-time high

79

Jan 2024

All-time low

13

Jan 2023

Average rank

36

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
1
7
5
9
Price/Earnings
1
1
3
9
Price/Book
1
8
5
9
Dividend Yield
1
1
1
1
Value (overall)
1
4
4
7

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Hanall Biopharma with its peers
Ilsung IS
KSC:003120
59
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kukje Pharma
KSC:002720
43
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Dongwha Pharm
KSC:000020
44
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Bora Pharmaceuticals
TAI:6472
27
CountryTaiwan
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Jeil Pharma
KSC:002620
73
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Reyon Pharmaceutical
KSC:102460
16
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →